1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Type 1 Diabetes Research Grants (The Leona M. and Harry B. Helmsley Charitable Trust) is sponsored by The Leona M.
and Harry B. Helmsley Charitable Trust. The Leona M.
and Harry B. Helmsley Charitable Trust funds programs focused on improving outcomes for people with type 1 diabetes and delaying the progression of type 2 diabetes. Their work also includes improving access to quality healthcare in rural communities.
Get alerted about grants like this
Get emailed when new opportunities from “The Leona M. and Harry B. Helmsley Charitable Trust” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Improving Lives Today, Investing in a Better Tomorrow Helmsley’s Type 1 Diabetes (T1D) Program is dedicated to helping the global T1D community live safer, better, and more fulfilling lives today while funding advancements in research and technology for a better tomorrow.
To make this vision a reality, our T1D program takes bold but informed risks to support researchers developing new therapies and interventions that can treat, prevent, or delay the disease. We are committed to equitable, affordable access to the tools that can help people with T1D achieve better outcomes.
Every day counts for people with T1D and their support network, which is why we build collaborative partnerships to expand the availability of resources to these communities. Over the last century, advances in therapies and technologies have drastically improved health and daily lives for many with T1D, but the risk of hospitalization and serious complications persists.
Managing T1D remains a lifelong, often mentally-taxing challenge that complicates everyday decisions around diet, exercise, and health. It requires around-the-clock management of blood sugar and regular administration of insulin, a drug that can cause hypoglycemia — low blood sugar that can be fatal — if not dosed correctly.
Meanwhile, treatments and technologies that can significantly reduce the burden of T1D are not available to everyone. T1D is an autoimmune disease in which the immune system mistakenly attacks beta cells in the pancreas. Beta cells produce insulin, an essential hormone that allows the body to metabolize food.
People with T1D depend on therapeutic insulin, administered multiple times a day, to regulate their blood sugar — without insulin, or if insulin is dosed improperly, T1D is fatal. In addition to the destruction of insulin-producing beta cells, in T1D the neighboring alpha cells are also dysregulated. Alpha cells produce glucagon, a hormone important for the response to low blood sugar — which can also be life-threatening.
T1D can develop at any age. The exact causes of T1D are unknown, but genetics and environmental influences are believed to contribute. Managing T1D can be incredibly taxing on people with T1D and their caregivers.
Because the risk of death is real and immediate, at Helmsley, we’re committed to easing this burden and improving outcomes for all people living with T1D.
##### How the Overlooked Alpha Cell Could Improve the Lives of Diabetes Patients ##### GentiBio Receives Grant from Breakthrough T1D and the Helmsley Charitable Trust to Support POLARIS Trial of GNTI‑122 in Recently Diagnosed Type 1 Diabetes ##### An Overlooked Intersection: T1D and Maternal Health ##### New Global Alliance ALIGN-T1D Commits to Transforming Diabetes Care in Low- and Middle-Income Countries ### Care Beyond the Clinic: Building Everyday Support for Type 1 Diabetes Type 1 diabetes (T1D)is a lifelong condition that requires constant attention—insulin, food, timing, and vigilance.
For the nearly 10 million people worldwide living with T1D,managing their health extends far beyond clinic visits or prescriptions. It takes place at kitchen tables, in school corridors, and in the decisions families make every day.
Handling those daily decisions can be overwhelming, especially in many low- and middle-income countries (LMICs), where that burden is intensified by limited access… ### African Governments Advance PEN-Plus at ICPPA 2026 In late June,the World Health Organization Regional Office for Africa (WHO AFRO)hosted the third International Conference on PEN-Plus in Africa(ICPPA)in Dar es Salaam,Tanzania.
This year,African health leaders didn’t come to hear about a promising pilot. They came to talk about scaling it. The discussion shifted from proving PEN-Plus works to building the systems needed to sustain it.
### NCQA Receives Grant From the Helmsley Charitable Trust to Advance High-Quality Diabetes Care Washington, D. C. and New York, N.
Y. , May 14, 2026 — The National Committee for Quality Assurance (NCQA) is proud to announce new funding from The Leona M. and Harry B.
Helmsley Charitable Trust to strengthen clinician and health plan accountability for delivering high‑quality diabetes care.
The three‑year initiative will advance quality of care for people living with type 1 and… ### The Health Equity Podcast Spoke With Type 1 Diabetes Program Officer James Reid Helmsley Type 1 Diabetes Program Officer James Reid joined Jayasree Iyer on the Access to Medicine Foundation’s Health Equity Podcast to talk about closing the gap in type 1 diabetes care for people in low- and middle-income countries.
As James puts it, “What really matters is how we align our resources, our will, and our efforts to make sure… ### World Diabetes Day 2025 Every year on World Diabetes Day, Helmsley partners with the Empire State Building and the Helmsley Building to light the New York City skyline blue and raise awareness about type 1 diabetes (T1D).
This tradition reflects our commitment to helping the global T1D community live safer, better, and more fulfilling lives. As we reflect on this day where the diabetes… #### King's College London Date of Award: 07. 22.
2026 #### Seattle Children's Hospital Date of Award: 06. 24. 2026 #### Board of Trustees of the Leland Stanford Junior University Date of Award: 06.
24. 2026 #### Fondation de soutien à l'Organisation Mondiale de la Santé Date of Award: 06. 10.
2026 #### International Alliance for Diabetes Action Inc Date of Award: 06. 10. 2026 Associate Program Officer Associate Program Officer Associate Program Officer Associate Program Officer Associate Program Officer Associate Program Officer Associate Program Officer
According to the current listing, eligibility includes: The Helmsley Charitable Trust primarily funds established organizations with a track record in diabetes research and care. Nonprofits engaged in relevant research and programs are eligible. Confirm the full requirements in the official notice before applying.
Type 1 Diabetes Research Grants (The Leona M. and Harry B. Helmsley Charitable Trust) is funded by The Leona M. and Harry B. Helmsley Charitable Trust. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Leona M. and Harry B. Helmsley Charitable Trust Rural Healthcare Program is sponsored by The Leona M. and Harry B. Helmsley Charitable Trust. This program funds innovative projects that use information technologies to connect rural patients to emergency medical care, bring the latest medical therapies to patients in remote areas, and provide state-of-the-art training for rural hospitals and EMS personnel.
Ultrasound Tuition Assistance Program (Minnesota) is sponsored by Minnesota Rural Health Association (MRHA) / The Leona M. and Harry B. Helmsley Charitable Trust. This program provides funding to healthcare organizations serving rural and underserved communities in Minnesota to train additional staff for ultrasound services, expand or sustain sonography staff, and increase ultrasound capabilities. It is part of a larger initiative to provide hospitals and health centers with ultrasounds and sonography training.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.